Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2OUZ

Crystal Structure of Estrogen Receptor alpha-lasofoxifene complex

Summary for 2OUZ
Entry DOI10.2210/pdb2ouz/pdb
Related1ERE 1ERR
DescriptorEstrogen receptor, (5R,6S)-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL (3 entities in total)
Functional Keywordsnuclear receptor, serm, estrogen, hormone-growth factor complex, hormone/growth factor
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight29302.57
Authors
Vajdos, F.F.,Pandit, J. (deposition date: 2007-02-12, release date: 2007-05-08, Last modification date: 2023-08-30)
Primary citationVajdos, F.F.,Hoth, L.R.,Geoghegan, K.F.,Simons, S.P.,LeMotte, P.K.,Danley, D.E.,Ammirati, M.J.,Pandit, J.
The 2.0 A crystal structure of the ER{alpha} ligand-binding domain complexed with lasofoxifene
Protein Sci., 16:897-905, 2007
Cited by
PubMed Abstract: Lasofoxifene is a new and potent selective estrogen receptor modulator (SERM). The structural basis of its interaction with the estrogen receptor has been investigated by crystallographic analysis of its complex with the ligand-binding domain of estrogen receptor alpha at a resolution of 2.0 A. As with other SERMs, lasofoxifene diverts the receptor from its agonist-bound conformation by displacing the C-terminal AF-2 helix into the site at which the LXXLL motif of coactivator proteins would otherwise be able to bind. Lasofoxifene achieves this effect by occupying the space normally filled by residue Leu 540, as well as by modulating the conformation of residues of helix 11 (His 524, Leu 525). A well-defined salt bridge between lasofoxifene and Asp 351 suggests that charge neutralization in this region of the receptor may explain the some of the antiestrogenic effects of lasofoxifene. The results suggest general features of ERalpha/SERM recognition, and add a new dimension to efforts to rationalize differences between the biological activity profiles exhibited by these important pharmacological agents.
PubMed: 17456742
DOI: 10.1110/ps.062729207
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon